Stock Idea - Zee News & Apollo Tyres

Zee News
Recommendation: Buy
CMP = Rs 60 (as of Monday)
Price target: Rs 73
 
Result highlights:
  • Zee News Ltd's (ZNL) Q2FY2008 results are in line with our expectations. The revenue from operations grew by a robust 46.2% year on year (yoy) to Rs 79.8 crore while the net profit zoomed by 154% to Rs 5.6 crore during the quarter.
  • The advertising revenues soared by 57% yoy to Rs 60.8 crore but the growth in the subscription revenues was a moderate 9.5% to Rs15 crore. A break-up of its channels into the existing and new businesses shows that revenues from the existing businesses grew by a handsome 42% yoy whereas the new businesses recorded an 80% growth in their revenues.
  • The operating profit margin (OPM) for the quarter stood at 13.3% against a dismal 1.5% for Q2FY2007. Thus the operating profit grew to Rs 10.6 crore against Rs0.8 crore in Q2FY2007. The existing businesses continued to maintain a good margin, which stood at 33% for the quarter. The operating loss of the new businesses was almost constant yoy at Rs 13.1 crore.
  • While Zee Marathi and Zee Bangla improved their leadership position during the quarter, the new channels, Zee Telugu, Zee Kannada and Zee 24 Ghanta, achieved commendable improvement in their Gross Rating Points (GRPs) yoy.
  • At the current market price of Rs 60.3 the stock trades at 28.8x its FY2009E earnings per share (EPS) of Rs 2.1 and at FY2009E market cap/sales of 3.3x.
  • I maintain Buy recommendation on the stock with price target of Rs 73 with a time frame of 8-12 months.
Apollo Tyres
Recommendation: Buy
CMP = Rs 40
Price target: Rs 52
 
Result highlights:
  • Apollo Tyres has rendered a brilliant performance for Q2FY2008 on the back of a strong topline growth. The quarterly performance has been further fuelled by an improvement in the operating profit margin (OPM) due to lower raw material prices.
  • The topline has grown by 10% to Rs 844.3 crore for the quarter, which has been led mainly by a volume growth of 9% and a realisation growth of 1%. The slowdown has continued in the original equipment (OE) business, whereas the replacement market has grown by a high single digit.
  • The OPM has improved substantially to 12.8% as against 7.8% last year on the back of softer raw material prices, improvement in price realisation, and increasing operating efficiencies. Consequently, the operating profit marked a growth of 81% to Rs 108.1 crore. A higher other income has enabled the net profit for the quarter to grow by 164.2% to Rs 51.1 crore.
  • On the consolidated basis, the net revenues have been flat at Rs 1,085 crore, while the profit has improved to Rs 57.6 crore (up 216% year on year [yoy]). The sales of its subsidiary Dunlop has been affected during the quarter due to a shutdown in September 2007, however the profitability has improved.
  • Dunlop is performing very well and the earnings before interest, depreciation, tax, and amortisation (EBIDTA) margin has reached the 12% level during the quarter. 
  • At the current market price of Rs 40, the stock discounts its FY2009E consolidated earnings by 7.6x and quotes at an enterprise value (EV)/EBIDTA of 4.9x.
  • I maintain Buy recommendation on the stock with a revised price target of Rs 52.

__________________________________________________
Do You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

Stock Idea - Wockhardt & Cadila Healthcare

Wockhardt

Recommendation: Buy

CMP = Rs 416 (as of Monday)

Price target: Rs 552

Result highlights:

  • Wockhardt's net sales increased by 68.6% to Rs 738.1 crore in Q3CY2007. The growth was achieved on the back of a 6.3% growth in the domestic business and a 121.1% growth in the international business. On a like-to-like basis (excluding the impact of the acquisitions made during the year), the growth stood at an approximate 9.0% during the quarter. The sales growth was above our estimates.
  • Wockhardt's domestic sales grew by a subdued 6.3% to Rs 213.2 crore in the quarter. The growth was subdued due to the high base of Q3CY2006 because of the increased sales of its acute therapy brands on account of the spread of monsoon-related infectious diseases. Wockhardt is confident of accelerating the domestic growth in Q4CY2007 on the back of a steady performance of the power brands, the ramp-up of the oncology portfolio and the growing contribution from the in-licenced products in the dermatology space. We estimate Wockhardt's domestic business would grow by 17.0% in CY2007 and by 12.5% in CY2008. 
  • Wockhardt's European business almost doubled during the quarter to Rs 433.0 crore, driven by a healthy double-digit growth of 14-15% across the existing markets of the UK and Germany, and the consolidation of Pinewood Laboratories and the recently acquired Negma Laboratories. 
  • Wockhardt's reported operating profit margin (OPM) expanded by 230 basis points to 24.5% in Q3CY2007. This was driven by a 300-basis-point reduction in the other expenses and a 230-basis-point dip in the research and development (R&D) expenses. The sharp decline in each of these expenses was due to the deferral of certain R&D and selling/administrative expenses to Q4CY2007. The company reported an operating profit (OP) of Rs 180.9 crore, a growth of 86.3% year on year (yoy).
  • Wockhardt's net profit stood at Rs 108.3 crore in the quarter, growing by 46.4% yoy. The profit growth was ahead of our estimates, despite a 50-fold increase in the interest expense (due to acquisitions), a 39% rise in the depreciation charge and a 360-basis-point increase in the tax incidence.
  • At the current market price of Rs 416, the stock is available at 13.3x its CY2007E and 11.9x its CY2008E earnings, on a fully diluted basis. The valuations seem very attractive at these levels and should be viewed as a strong buying opportunity.
  • I maintain Buy recommendation on the stock with a price target of Rs 552 with a time frame of 12 months.

 

Cadila Healthcare

Recommendation: Buy

CMP = Rs 300 (as of Monday)

Price target: Rs 425

Result highlights:

  • Cadila Healthcare's (Cadila) total operating income (consolidated) grew by a healthy 28.4% year on year (yoy) to Rs 609.7 crore in Q2FY2008. The growth was driven by a 12.3% growth in the domestic business and a 64.0% growth in the exports. The sales growth was in line with our estimates. The consolidation of the recently made acquisitions also contributed to the overall growth. Excluding the impact of these acquisitions, the like-to-like growth stood at around 18.1%.
  • Cadila's domestic formulation business grew by a subdued 6.6% to Rs316.3 crore in Q2FY2008. The growth was low during the quarter due to the high base of Q2FY2007, when the company had recorded strong sales due to the outbreak of monsoon-related diseases like malaria and chikungunya. However, as per the secondary sales data complied by ORG-IMS, Cadila's sales have been growing at 15%. The company believes that it is on track to achieve a 14-15% growth in this business in FY2008 and hence expects an acceleration in the growth in H2FY2008.
  • Cadila's operating profit margin (OPM) shrank by 140 basis points to 21.6% in Q2FY2008. The contraction in the margin was largely due to a 49.9% rise in the staff cost due to the consolidation of Nikkho, which has a higher staff cost component. On the other hand, the gross margin improved by 190 basis points to 67.3%, once again due to the consolidation of Nikkho, which enjoys a gross margin of up to 80% as it operates in the branded product space in Brazil. Consequently, Cadila's operating profit grew by 20.8% to Rs 131.7 crore in Q2FY2008. 
  • Despite a doubling of the interest expenses (due to the acquisitions), the pre-exceptional net profit grew by 17.0% to Rs 82.5 crore. The net profit was affected by a foreign exchange (forex) loss of Rs 2.2 crore recorded during the quarter and was marginally above our estimates. The earnings for the quarter stood at Rs 6.6 per share.
  • At the current market price of Rs 300, the company is trading at 13.4x its FY2008 and 11.4x its FY2009 estimated earnings.
  • With all the growth drivers in place, I maintain Buy recommendation on Cadila with a price target of Rs 425 for a time frame of 12 months.

Stock Idea - Union Bank of India

Recommendation: Buy
CMP = Rs 162 (as of Monday)
Price target: Rs 230
 
Result highlights:
  • Union Bank of India's (UBI) net profit increased by 41.9% year on year (yoy) to Rs 275.5 crore in Q2FY2008. The growth was mainly driven by a 77.4% year-on-year (y-o-y) increase in the non-interest income category, as the net interest income (NII) growth at 7.2% yoy was weak. Lower operating expenses, which grew by 6.2% yoy, also helped to improve the earnings growth at to 41.9%. 
  • During the quarter, the bank's NII increased by 7.2% yoy but declined by 12.8% on a sequential basis. The net interest margin (NIM) of the bank was down by 20 basis points yoy and by 55 basis points sequentially at 2.56%. The sequential decline in the NIM was mainly due to the 61-basis-point increase in the cost of funds. The substantial sequential jump in the bank's cost of funds was mainly due to a higher cost of deposits arising from a decline in the low-cost deposit base and a rise in the high-cost term deposit base. 
  • The positive takeaway for the quarter has been the growth in the non-interest income but that too was driven by higher treasury income and recoveries as the core fee income grew by a moderate 11.3%. 
  • The operating expenses grew by a moderate 6.2% yoy that helped the bank in reporting a better operating profit growth of 35.8% yoy and 0.6% qoq. The core operating profit growth was however much lower at 18.4% yoy and declined by 11.2% sequentially. 
  • The provisions and contingencies dropped 36.9% on a sequential basis mainly due to the absence of investment depreciation on IFCI bonds and a Rs35-crore write-back in excess non-performing asset (NPA) provisions during the current quarter. However, the provisions are up by 18.1% yoy, in line with the business growth. The asset quality has improved on a sequential basis with the net non-performing asset (NNPA) at 0.65% as in September 2007 compared with 0.78% in September 2006. 
  • Currently, the low credit growth seems to be the main concern as the NIM is likely to stabilise as banks have already started to cut deposit rates. UBI has been one of the better performing public sector banks with a 23.6% compounded annual growth rate (CAGR) in earnings for the period FY2007-09E and a high return on equity of 21.5%.
  • At the current market price of Rs162, the stock is quoting at 6.3x its FY2009E earnings per share (EPS), 3.3x pre-provision profit (PPP) and 1.3x book value (BV).
  • I maintain Buy recommendation on the stock with a revised 12-month price target of Rs 230.

Stock Idea - Sun Pharmaceutical Industries

Recommendation: Buy
CMP = Rs 1,042
Price target: Rs 1,287
 
Result highlights:
  • Sun Pharma reported a strong top line growth of 24.6% year on year (yoy) in Q2FY2008 to Rs 667.9 crore. The top line was significantly higher than our estimate of Rs 632 crore. The strong growth was driven by an increase of 26.3% in its domestic business and a 19.2% growth in its exports.
  • The domestic formulation business grew by 31.2% to Rs 372.0 crore. This quarter was phenomenal for this business, which saw the highest ever revenues and growth rates. Going forward, the company expects the growth to moderate to more sustainable levels.
  • I believe Sun Pharma's domestic formulation business will continue to outpace the industry and grow at a compounded annual growth rate (CAGR) of 20% over FY2007-09.
  • Caraco Pharma, Sun Pharma's US subsidiary, continued with its impressive performance by registering a 46% growth in the revenue to $41.4 million (against our estimate of $37 million) and a 100% jump in the net profit to $4.6 million in the quarter. 
  • Sun Pharma demonstrated excellent cost control during the quarter, with margins expanding by 420 basis points to 36.1%, the highest operating profit margin (OPM) reported by the company so far. The margin expansion caused the operating profit (OP) to grow by a robust 41.0% to Rs 240.9 crore in Q2FY2008. 
  • Despite a robust operating performance, Sun Pharma's net profit growth was restricted to just 17.2% at Rs 218.6 crore during the quarter. The profit was in line with our estimate of Rs 213 crore. The profit growth slowed down due to the sharp 72% reduction yoy in the other income. 
  • Sun Pharma's recent wins in the Para IV patent challenges indicate the future potential of its US business. The company has recently announced favourable outcomes on four Para IV challenges, generic Protonix, generic Trileptal, generic Effexor XR and generic Exelon, thus winning a 180-day exclusivity (in certain cases, the same is shared with a few other players) for supplying these products in the USA.
  • While the company is still evaluating its launch options for generic Protonix and generic Exelon, it has already launched generic Trileptal and is awaiting the US Food and Drug Administration's (US FDA) approval for generic Effexor XR. Upon receiving the approval it will evaluate the latter's launch and/or settlement options.
  • Taro has further pushed its shareholders' meet until after the announcement of its audited results for 2006 and H1CY2007. There is no clarity on the timeline of the result announcements. With a 25% stake in Taro, Sun Pharma's management remains confident of closing the transaction after the shareholders' meeting.
  • At the current market price of Rs 1,042, Sun Pharma is valued at 23.3x FY2008E and 19.6x FY2009E fully diluted earnings.
  • I maintain Buy recommendation on the stock with a price target of Rs 1,287 over a time frame of 12 months.

__________________________________________________
Do You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

Stock Idea - Marico

Recommendation: Buy
CMP = Rs 63
Price target: Rs 70
 
Result highlights:
  • The Q2FY2008 results of Marico were as per our expectations. In Q2FY2008, the net revenues of the company grew by 22.7% year on year (yoy) to Rs 463.8 crore. The growth was driven by a 16% organic growth and a 7% inorganic growth.
  • The operating profit margin (OPM) declined by 81 basis points to 13.95% on account of a higher raw material cost, which as a percentage of sales increased by 210 basis points to 51.6%. Consequently, the operating profit grew by 16% yoy to Rs 64.7 crore.
  • A substantial decline of 49.3% in the depreciation charge due to a write-off of intangibles in FY2007 along with a tax incidence of just 19.3% (compared with 30.9% in Q2FY2007) led to a 63% jump in net profit to Rs 42.2 crore.
  • The quarter witnessed a good volume growth across products with Parachute coconut oil growing by 8%, focus segment products growing by 15% and Saffola growing by 21% yoy. The international consumer product business grew by a strong 73% aided by the Egyptian business.
  • Also, the chain of Kaya clinics expanded to 51 as the company added three new clinics during the quarter.
  • I maintain a positive outlook on the company and expect its turnover to grow by 21% in the current financial year. The stock is trading at valuations of 18.8x FY2009E earnings per share (EPS) and enterprise value (EV)/earnings before interest, depreciation, tax and amortisation (EBIDTA) of 12.4x FY2009E.
  • I maintain Buy recommendation on the stock with a price target of Rs 70.

__________________________________________________
Do You Yahoo!?
Tired of spam? Yahoo! Mail has the best spam protection around
http://mail.yahoo.com

Stock Idea - Zensar Technologies

Recommendation: Hold
CMP = Rs 188 (as of Tuesday)
Price target: Rs 380
 
Result highlights:
  • Zensar Technologies (Zensar) reported a disappointing growth of 2.1% quarter on quarter (qoq) and of 29% year on year (yoy) in its consolidated revenues to Rs 191.8 crore during the second quarter ended September 2007. The sequential growth in its revenues was lower than expectations and driven by a volume growth of around 4% on a sequential basis. 
  • However, the operating profit margin (OPM) improved by 79 basis points to 10.5%, which is ahead of our expectations. That's because the annual salary hikes given in Q2 had an adverse impact of 230 basis points (or Rs4.5 crore) on the margin. This was more than mitigated by the leverage in the overheads cost.
  • The earnings grew at a relatively higher rate of 5.4% qoq (17% yoy) to Rs 14.2 crore, which is again lower than our expectations of Rs 15 crore.
  • The company has guided for revenues of Rs 800 crore and earnings of Rs70 crore (down from Rs80 crore given earlier) in FY2008. Even the downgraded earnings guidance implies a sequential growth of around 30% compounded quarterly growth rate (CQGR) over the next two quarters.
  • However, the management is confident of achieving the same on the back of a considerable growth in volumes (the company signed some significant contracts recently; it expects a smart uptick in the enterprise application services [EAS] segment due to a revival in the performance of ThoughtDigital) and margin expansion (driven by a rate hike of 4-6% from some of its top accounts, leverage in the overheads cost and operational efficiencies). 
  • At the current market price the stock trades at 6.7x FY2008 and 5.6x FY2009 earnings estimates. Though the valuations are compelling, I still maintain Hold recommendation on the stock and would review recommendation based on the performance in the coming quarters.

Stock Idea - Surya Pharmaceuticals

Recommendation: Buy
CMP = Rs 106
Price target: Rs 205
 
Result highlights:
  • Surya Pharmaceutical (Surya) reported a massive 90.1% increase in its top line to Rs 118.1 crore in Q2FY2008. The growth was driven by the increase in the company's existing active pharmaceutical ingredient (API) business and a 6-7% contribution from the new business of menthol and its derivatives. The sales growth was in line with our estimates. 
  • Surya's operating profit margin (OPM) shrank by 280 basis points to 17.8% in the quarter, primarily due to a 100.4% increase in the raw material cost. The increase in the material cost was due to the rising Penicillin-G (Pen-G) prices worldwide. However, going forward, the management has indicated that Pen-G prices have now stabilised and the raw material cost should show a marginal improvement in the coming quarters. Consequently, the company's operating profit grew by 64.0% to Rs 21.0 crore in the quarter.
  • Surya's net profit grew by an impressive 83.7% to Rs 11.7 crore in Q2FY2008 and was in line with our estimate. The net profit growth was strong despite a 48.1% increase in the interest expense and an 11.3% rise in the depreciation charge. The earnings for the quarter stood at Rs 8.1 per share.
  • Surya began exporting menthol and its derivatives only in mid-August 2007 and hence the Q2FY2008 results do not reflect the full quarter impact of the menthol business. I expect Surya to deliver a stronger performance in H2FY2008 on the back of steady revenues from the existing API business and growing revenues from the menthol business. 
  • At the current market price of Rs 106, Surya is trading at 4.6x its FY2008E diluted earnings of Rs 23.2 and 3.3x its FY2009E diluted earnings of Rs 32.1.
  • At the current prices, Surya offers a remarkable combination of strong growth at cheap valuations. I view this as a strong buying opportunity and hence maintain Buy call on the stock with a price target of Rs 205.
 

© blogger templates 3 column | Make Money Online